Q-omics provides the consensus-scored L3MBTL1 profile across patient tissues and cancer cell-line models. L3MBTL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, L3MBTL1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, L3MBTL1 RNA expression shows 20,647 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where L3MBTL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for L3MBTL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes L3MBTL1 survival associations across molecular data types. L3MBTL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible L3MBTL1 RNA expression–survival associations across cancer types. High L3MBTL1 expression shows unfavorable associations in KIRC and COAD, but favorable associations in BLCA, SKCM, PAAD and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for L3MBTL1 RNA expression.
This table summarizes L3MBTL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for L3MBTL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. L3MBTL1 shows lower tumor expression in BRCA and higher tumor expression in COAD, LIHC, CHOL, LUSC and KIRP. The COAD box plot shows higher L3MBTL1 RNA expression in tumor versus normal tissue (log2 FC = +0.848, t-test p < 0.001).
This table shows molecular features associated with L3MBTL1 in patient tissues and cancer cell lines. In patient samples, L3MBTL1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, L3MBTL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
